Dow Tumbles 150 Points; US House Prices Rise in July
Portfolio Pulse from Lisa Levin
US stocks traded lower with the Dow Jones falling around 150 points. The S&P CoreLogic Case-Shiller 20-city home price index rose 0.1% YoY in July, the first rise in five months. Soleno Therapeutics, Femasys Inc., and Intercept Pharmaceuticals saw significant stock price increases, while TransCode Therapeutics, Murphy Canyon Acquisition Corp., and Polished.com Inc. experienced notable declines.
September 26, 2023 | 1:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Femasys Inc. shares rose 277% after receiving FDA 510(k) clearance for FemaSeed, an infertility treatment.
The FDA clearance for FemaSeed is a major regulatory milestone for Femasys Inc., likely leading to increased investor confidence and a rise in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Intercept Pharmaceuticals shares gained 77% after Alfasigma agreed to acquire the company for $19.00 per share in cash.
The acquisition agreement with Alfasigma is a significant event for Intercept Pharmaceuticals, likely leading to increased investor confidence and a rise in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Soleno Therapeutics shares shot up 383% after releasing top-line results from a study of DCCR for Prader-Willi Syndrome.
The positive study results for DCCR are a significant development for Soleno Therapeutics, likely leading to increased investor confidence and a surge in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
Shares of Murphy Canyon Acquisition Corp. were down 32% after dipping 38% on Monday.
The continued decline in the stock price of Murphy Canyon Acquisition Corp. likely indicates a decrease in investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
Polished.com Inc. was down, falling 25% after surging 40% on Monday.
The sharp decline in the stock price of Polished.com Inc. following a surge likely indicates a correction or a decrease in investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
TransCode Therapeutics shares dropped 64% after pricing its $8 million public offering of 15.7 million shares at $0.51 per share.
The pricing of the public offering at a lower price likely led to a decrease in investor confidence and a drop in the stock price of TransCode Therapeutics.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100